The Albany Prize has been awarded annually since 2001 and was established by the late Morris “Marty” Silverman, whose vision was to celebrate scientists whose work exemplifies the “bench to bedside” arc of modern biomedical research: fundamental discoveries made at the laboratory bench that ultimately translate into treatments that measurably improve the lives of patients across the country and around the globe. That mission is underwritten by a $50 million gift commitment from the Marty and Dorothy Silverman Foundation to Albany Medical Center, a commitment that guarantees the prize can be conferred for 100 years and has helped build its reputation to a level often described as approaching that of the Nobel Prize. Past recipients read like a roster of modern biomedical history, including former National Institute of Allergy and Infectious Disease director Anthony Fauci, CRISPR pioneers and Nobel Laureates Emmanuelle Charpentier and Jennifer Doudna, and mRNA vaccine pioneers and Nobel Laureates Katalin Karikó and Drew Weissman, among many others. Hunter’s inclusion in that company reflects the sheer reach of a single biochemical insight made more than four decades ago.

That insight concerns a molecular switch known as tyrosine phosphorylation. Phosphorylation, the process by which enzymes attach phosphate groups to amino acids within proteins, is one of the cell’s most fundamental control mechanisms, a way of flipping proteins between functional states in response to signals. For years, scientists knew that phosphate groups could be attached to the amino acids serine and threonine. What Hunter discovered in 1979, quite by accident, was that phosphate could also be linked to a third amino acid: tyrosine. The finding revealed an entirely new class of regulatory enzymes, the tyrosine kinases, which add phosphate groups to tyrosine residues and in doing so help govern how cells grow, divide, and communicate with their surroundings.

The discovery itself is a textbook example of serendipity rewarding careful observation. Hunter was conducting an experiment to separate the amino acids in a viral protein, a routine analytical procedure that depended on a buffer, a solution used to control acidity. Unknowingly, he used a buffer with a pH of 1.7 instead of the intended 1.9. That tiny difference in acidity, a shift of just two-tenths of a pH unit, altered the chemical behavior of the phosphorylated amino acid in his sample just enough to expose what had previously been hidden: a phosphate group sitting on a tyrosine residue. Had the pH been exactly as planned, the modification might have gone undetected. “A gratifying outcome of this set of experiments on a simple chicken tumor virus,” Hunter later wrote of the episode in a 2015 perspective published in the Proceedings of the National Academy of Sciences, a wry acknowledgment that a humble reagent error had opened a vast new field of cancer biology.

What followed the 1979 landmark study was a career of persistent, systematic elaboration. Hunter went on to write and publish many additional papers on this new protein kinase family, methodically characterizing how tyrosine kinases work and how they are controlled. Through that sustained curiosity, he came to a realization that would transform medicine: tyrosine kinases become overactive in many human cancers. When the molecular switches that regulate cell growth become stuck in the on position, cells proliferate uncontrollably. Identifying tyrosine phosphorylation therefore did more than add a line to biochemistry textbooks; it handed cancer researchers a specific, druggable target. If overactive tyrosine kinases drive malignancy, then molecules designed to block those enzymes might stop tumors in their tracks.

That logic produced one of the great success stories of modern oncology. In 2001, the U.S. Food and Drug Administration approved imatinib, known commercially as Gleevec, the first in a revolutionary class of drugs called tyrosine kinase inhibitors. Imatinib transformed the treatment of chronic myelogenous leukemia, converting what had been a terminal disease into a highly manageable condition for many patients. It was the proof of principle that Hunter’s foundational discovery could be turned directly into lifesaving therapy. Today, more than 100 cancer drugs that block overactive tyrosine kinases exist, all of them tracing their conceptual origin to Hunter’s identification and characterization of the tyrosine kinase family. Few basic science discoveries can claim a pharmacological legacy of that scale, and it is precisely this bench-to-bedside trajectory that the Albany Prize was created to honor.

Hunter shares the 2026 prize with Dennis Slamon of UC Los Angeles, whose own cancer biology discoveries have likewise translated into therapies with global impact. The pairing of the two laureates underscores a theme that runs through the Albany Prize’s history: the award seeks scientists whose laboratory insights have demonstrably reached patients. In Hunter’s case, the chain of translation runs from a chicken tumor virus experiment in 1979, through decades of enzymology and signal transduction research, to a pharmacopoeia of kinase inhibitors now deployed in clinics worldwide. Gerald Joyce, MD, PhD, president of the Salk Institute, praised Hunter’s approach to science in announcing the honor. “Tony’s dedication to curiosity-driven research has made him an irreplaceable asset at Salk and in science at large,” Joyce said. “His commitment to foundational discovery has transformed cancer biology and treatment, and we look forward to celebrating this honor with him.”

Remarkably, the discovery that anchors this award is not the endpoint of Hunter’s career but a chapter in its middle. The year 2025 marked his 50th at the Salk Institute, where he remains an active researcher, pursuing his own collaborations and projects while taking evident pride in training the next generation of cancer biologists and life sciences researchers. His perspective on the unfinished nature of biology is one he shares directly with his students. “When I’m teaching students, I say an awful lot has already been discovered, but an awful lot remains unknown. I’m sure that new biological principles will emerge that we can’t even imagine right now,” Hunter said in a 2023 feature in Inside Salk magazine. “I’m excited because there will always be new things to be discovered for as long as I’m alive.” It is a sentiment that captures the ethos of curiosity-driven research that colleagues credit for his longevity and productivity at the bench.

The Albany Prize adds a distinguished new item to an already crowded shelf of accolades. Hunter’s earlier honors include the Wolf Prize in Medicine, the Gairdner Foundation International Award, the Louisa Gross Horwitz Prize, the National Cancer Institute Outstanding Investigator Award, the American Association for Cancer Research Lifetime Achievement Award in Cancer Research, the Sjöberg Prize for Cancer Research, the Prince Mahidol Award, and the Dr. Paul Janssen Award for Biomedical Research. He has also been elected a fellow of the American Association for Cancer Research, a Member of the American Philosophical Society, a fellow of the Royal Society of London, a Member of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, and a Member of the National Academy of Medicine. Each of these recognitions, like the Albany Prize itself, circles back to the same origin: a two-tenths-of-a-pH-unit error in 1979 that revealed how a phosphate group on a single amino acid could unlock the molecular logic of cancer, and ultimately the drugs that hold it in check for millions of patients.

Subject of Research: Recognition of Tony Hunter's discovery of tyrosine phosphorylation and its role in targeted cancer drug development

Article Title: Salk scientist Tony Hunter receives 2026 Albany Prize

Article References: Salk scientist Tony Hunter receives 2026 Albany Prize. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Tony Hunter, Albany Prize, tyrosine phosphorylation, tyrosine kinases, cancer drugs, imatinib, Gleevec, Salk Institute, chronic myelogenous leukemia, signal transduction, biomedical research award, Dennis Slamon

BCR-ABL1 is the fusion protein born from the Philadelphia chromosome, the hallmark genetic abnormality of chronic myeloid leukemia and a subset of B-cell acute lymphoblastic leukemia. First described in landmark reviews by Goldman and Melo, the fusion fuses the BCR gene on chromosome 22 with the ABL1 tyrosine kinase gene on chromosome 9, producing a constitutively active kinase that drives uncontrolled proliferation and survival of white blood cells. Tyrosine kinase inhibitors were designed to slip into the ATP-binding pocket of ABL1 and freeze the enzyme in an inactive state. In structural studies of the kinase domain, including work by Cowan-Jacob and colleagues, imatinib and related compounds achieve exactly that. And yet, in patients, the kinetics of treatment response are markedly slower than direct enzyme inhibition would predict, an effect sometimes described as target sluggishness.

The new research reframes this sluggishness as an emergent property of how BCR-ABL1 organizes itself inside the cell. Rather than floating freely through the cytoplasm as isolated molecules, the team found that BCR-ABL1 molecules condense into dense, membraneless assemblies reminiscent of liquid droplets. These condensates form through multivalent, weak interactions among intrinsically disordered regions of the protein, the same class of physical chemistry that governs the formation of cellular structures such as nucleoli, stress granules and P bodies. The study connects this condensate behavior directly to therapeutic response: when BCR-ABL1 resides within these droplets, the local molecular environment becomes a physical barricade that slows the entry and action of tyrosine kinase inhibitors.

The concept of phase separation has transformed cell biology over the past decade. In a widely cited 2018 paper in Cell, Qamar and colleagues demonstrated that low-complexity protein domains can undergo liquid-liquid phase separation, creating compartments whose material properties dictate how molecules exchange with the surrounding cytoplasm. The new study applies this framework to cancer signaling for the first time in the context of targeted therapy. The authors showed that disrupting the conditions that promote condensate formation made BCR-ABL1 more accessible to drugs, while conditions that stabilized the droplets exaggerated the sluggish response. The droplet, in effect, functions as a microscopic shelter: drug molecules can reach the droplet surface, but penetrating the dense interior to reach every kinase molecule takes far longer than engaging freely diffusing protein.

Technically, the researchers combined protein biochemistry with cellular assays and clinical material. They purified BCR-ABL1 protein and observed its condensation behavior in solution, finding that the protein spontaneously demixes from the aqueous phase to form spherical droplets that fuse with one another and exchange internal contents, hallmarks of a liquid state. In cells, they visualized BCR-ABL1 condensates and correlated their abundance with the speed and completeness of kinase inhibition after tyrosine kinase inhibitor treatment. Crucially, the team collected bone marrow and blood samples from patients with BCR-ABL1-positive leukemia through collaborations with clinicians at Zhejiang Cancer Hospital and the First Hospital of China Medical University, allowing them to test whether condensate behavior in patient-derived cells tracked with treatment response.

The clinical implications of this reframing are substantial. Resistance to tyrosine kinase inhibitors has traditionally been attributed to kinase domain mutations, most famously the T315I substitution that abolishes imatinib binding, or to the persistence of leukemic stem cells that are intrinsically insensitive to the drugs. Studies such as those by Braun and colleagues and by Schneider and colleagues in Nature Cancer have catalogued the biology of these persistent cells, which survive initial therapy and fuel relapse. The phase separation model adds an entirely orthogonal mechanism: a cell can carry a completely drug-sensitive kinase and still mount a delayed response simply because its target protein is packaged inside droplets that physically exclude or retard drug penetration. This innate, non-genetic sluggishness could explain why a measurable fraction of cells in every treated patient survives the earliest hours and days of therapy without carrying any resistance mutation at all.

The finding also resonates with earlier structural and biochemical work on the ABL1 kinase. Structures of ABL1 bound to imatinib, dasatinib and nilotinib published by Tokarski and colleagues revealed exactly how these compounds lock the kinase in its inactive conformation, and kinetic studies showed rapid association rates in purified systems. The paradox between fast in vitro inhibition and slow cellular response now finds a candidate resolution: the purified enzyme in a test tube has no condensate, no barrier and no sluggishness, while the same enzyme inside a leukemic cell is wrapped in a liquid compartment that throttles drug access. Zhao and colleagues’ early structural characterization of the BCR-ABL1 complex, and Smith and colleagues’ dissection of its signaling architecture, provided the molecular map; phase separation now supplies the cellular geography that shapes how drugs navigate that map.

From a therapeutic standpoint, the study suggests that modulating condensate properties could become a strategy to sensitize leukemic cells to existing drugs. If the physical barrier created by BCR-ABL1 condensates is a principal cause of sluggish drug response, then agents that dissolve or destabilize the droplets, or that alter the material properties of the condensate so that small molecules diffuse through it freely, could accelerate and deepen the effect of tyrosine kinase inhibitors. Conversely, the work raises a caution for drug development: potency measured against purified kinase may systematically overestimate how quickly a compound will work in a cell whose target is phase-separated. Screening platforms that incorporate condensate-relevant conditions could help identify compounds that retain efficacy against droplet-sequestered targets, particularly for B-cell acute lymphoblastic leukemia, where early response kinetics strongly influence long-term outcome, as population studies by Qin and colleagues and reports by Ravandi and Molica have documented.

The broader significance extends beyond a single kinase or a single disease. Cancer biologists have increasingly recognized that many oncogenic proteins contain the disordered, multivalent regions that drive phase separation, and that signaling complexes such as those assembled by fusion oncoproteins, including the EML4-ALK and NUP98 fusions studied by Dixon and colleagues in engineered systems, may exploit condensation to amplify and sustain their signals. The BCR-ABL1 study demonstrates that this same organizational principle can also serve as a defensive architecture against therapy. Pendergast and colleagues’ classic 1991 work showed that BCR sequences activate ABL1 tyrosine kinase; three decades later, the new findings suggest that those same BCR-derived regions may coil the fusion protein into droplets that protect the activated kinase from the drugs designed to silence it.

For patients with chronic myeloid leukemia, tyrosine kinase inhibitors have converted a uniformly fatal disease into a manageable chronic condition, and a minority of patients now attempt treatment-free remission under close monitoring. Yet discontinuation fails in a substantial fraction, and persistent cells endure for years. By exposing the physical mechanism behind innate sluggishness, this research opens a new front in the effort to eliminate residual disease: rather than only designing better inhibitors, oncologists may one day prescribe drugs that strip away the droplet shield itself. The image of a cancer protein hiding inside a liquid droplet is a vivid one, and it captures a larger truth about modern biology. Cancer is not only a disease of genes and pathways but of physical organization, and conquering it may require manipulating not just what proteins do, but where and how they gather inside the cell.

Subject of Research: Phase-separated BCR-ABL1 condensates that delay the response of leukemic cells to tyrosine kinase inhibitor therapy

Article Title: Phase separation drives the innate sluggishness of BCR-ABL1 in response to targeted therapy

Article References: Li, G., Wu, J., He, Z., Zhao, J., Chen, H., Zhou, J., Zhang, Q., Wang, Z., Li, Q., & Jiang, P. (2026). Phase separation drives the innate sluggishness of BCR-ABL1 in response to targeted therapy. Cell Research. https://doi.org/10.1038/s41422-026-01286-w

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01286-w

Keywords: BCR-ABL1, phase separation, chronic myeloid leukemia, tyrosine kinase inhibitors, condensates, imatinib, targeted therapy, leukemia, drug resistance, liquid-liquid phase separation, oncology, cell biology

The introduction of tyrosine kinase inhibitors, particularly imatinib, transformed the treatment landscape for advanced GIST, converting a rapidly fatal disease into a chronic but ultimately progressive condition for many patients. Complete surgical resection remains the standard of care for localized disease, yet a substantial proportion of high-risk patients still experience recurrence. In the metastatic setting, sequential therapy with agents such as sunitinib and regorafenib prolongs survival, but secondary resistance driven by clonal evolution eventually emerges in most cases. Against this backdrop, clinicians have long grouped together two very different patient populations: those who arrive with metastases already present at initial diagnosis, and those who develop metastases only after undergoing curative-intent surgery. Whether these two groups truly share the same prognosis has never been rigorously tested—until now.

In a study published in Annals of Gastroenterological Surgery, investigators from the Kinki GIST Study Group analyzed registry data collected from 46 institutions across two registration periods spanning 2003 to 2012. Of 1,426 registered patients with GIST, 147 individuals with metastatic disease formed the final analytical cohort: 51 patients had synchronous metastases, meaning metastatic disease was identified at or before the initial diagnosis of the primary tumor, while 96 patients had metachronous metastases, defined as metastatic lesions detected after curative-intent surgery, regardless of the interval. The researchers compared overall survival between these groups and then drilled deeper into the metachronous cohort, asking whether the interval between primary resection and recurrence—early, within two years, or late, beyond two years—further stratified outcomes.

The two groups were broadly comparable at baseline. Median age was 65 years in both, and the proportions of male patients were similar. Liver metastases were the dominant metastatic site in both cohorts, observed in roughly 55 percent of synchronous and 65 percent of metachronous cases, although peritoneal involvement was notably more common among synchronous patients at 54.9 percent versus 33.3 percent. One striking difference emerged: primary tumors were substantially larger in the synchronous group, with a median size of 12 centimeters compared with 7.5 centimeters in the metachronous group, and a categorical analysis using a 50-millimeter cutoff confirmed this imbalance. Mitotic counts, by contrast, were nearly identical between groups, suggesting that proliferative activity alone could not explain any survival differences that followed.

The survival results were unambiguous. Over a median follow-up of 74.2 months, the median overall survival for the entire cohort was 10.9 years. Patients with metachronous metastases lived significantly longer than those with synchronous disease, with median survival of 12.8 years versus 6.7 years—a difference of more than six years that reached statistical significance. Crucially, the advantage held up under scrutiny. In a multivariable Cox proportional hazards model adjusted for age, sex, primary tumor location, metastatic site, tumor size, and mitotic count, synchronous metastasis remained an independent predictor of death, carrying a hazard ratio of 2.36. In other words, even after accounting for every conventional clinicopathological factor available, the timing of metastatic onset nearly doubled the risk of dying during the study period.

Subgroup analyses reinforced the consistency of the finding. The survival disadvantage of synchronous disease was evident in both men and women, and it remained significant among patients younger than 75 years, though it did not reach statistical significance in the oldest age group, likely reflecting limited sample size. When stratified by primary tumor location, both gastric and small intestinal GIST showed a trend toward better outcomes in metachronous disease. Most intriguingly, the effect was site-dependent: among patients with liver metastases, the survival difference between synchronous and metachronous disease was significant, whereas among those with peritoneal metastases it disappeared entirely. This pattern echoes observations in colorectal cancer, where the prognostic weight of metastasis timing appears stronger in liver-limited disease and attenuates in peritoneal cohorts, hinting that metastatic biology and therapeutic feasibility jointly shape outcomes.

The second major finding concerned patients whose disease returned after surgery. Within the metachronous group, 55 patients experienced early recurrence within two years of resection and 41 experienced late recurrence beyond that threshold—a cutoff chosen because previous work by the same group showed that roughly 60 percent of GIST recurrences cluster within the first two postoperative years. Early recurrence carried a dramatically worse prognosis: overall survival differed significantly between the two groups. Notably, mitotic count did not differ meaningfully between early and late relapsers, suggesting that the recurrence interval captures dimensions of tumor behavior that standard proliferation measures fail to reflect. Adjuvant imatinib use was similar across both groups, although the duration of therapy was markedly shorter among early relapsers, a difference the authors acknowledge could influence but likely does not fully explain the survival gap.

What might underlie these patterns? The study was not designed to probe mechanisms, but the authors offer a cautious interpretation: synchronous and metachronous metastatic GISTs may represent biologically distinct entities. Tumors that have already disseminated by the time of diagnosis may harbor more aggressive clonal architectures from the outset, while tumors that recur late may have been biologically indolent for years before escaping control. This framework aligns with findings in metastatic renal cell carcinoma, non-small cell lung cancer with brain metastases, and metastatic pancreatic adenocarcinoma, where metachronous disease consistently outperforms synchronous disease in the era of targeted and immune-based therapies. In GIST, where prolonged tyrosine kinase inhibitor exposure drives clonal evolution and secondary resistance, the distinction could be even more consequential, potentially guiding how aggressively clinicians surveil and treat different patient subsets.

The authors are careful to frame their conclusions as hypothesis-generating rather than definitive. The retrospective design invites selection bias and residual confounding. The study period predates contemporary guidelines recommending at least three years of adjuvant imatinib for high-risk patients, and detailed data on systemic therapy sequences, metastasectomy, and molecular subtypes were not systematically captured. Mutation status, including KIT and PDGFRA genotypes, was unavailable for most participants, precluding exploration of whether metastasis timing correlates with specific genomic profiles. Furthermore, because survival was measured from the time of metastatic diagnosis, patients with metachronous disease must by definition survive long enough to relapse, introducing a potential guarantee-time bias that may favor this group. Subgroup analyses by metastatic site and age were also constrained by sample size.

Even with these caveats, the clinical implications are tangible. The findings suggest that metastasis timing deserves a place alongside tumor size, mitotic index, and anatomic site in prognostic discussions, and they lend support to intensified surveillance during the first two postoperative years, when the bulk of recurrences occur and when early relapse signals a particularly aggressive phenotype. Whether extended adjuvant imatinib can reshape the prognostic landscape of early versus late recurrence remains an open question for future trials. For now, this study offers oncologists a deceptively simple insight drawn from nearly a decade and a half of real-world Japanese registry data: in metastatic GIST, the calendar may matter as much as the microscope, and the moment a tumor reveals its spread could be one of the most informative data points a clinician possesses.

Subject of Research: The prognostic impact of synchronous versus metachronous metastasis timing on survival in metastatic gastrointestinal stromal tumors

Article Title: Prognostic Impact of Metastasis Timing in Metastatic Gastrointestinal Stromal Tumors: A Multicenter Retrospective Cohort Study

Article References: Kawai, K., Takahashi, T., Teranishi, R., Sato, S., Kurokawa, Y., Nishida, T., Hirota, S., Fujita, J., Doki, Y., & Tsujinaka, T. (2026). Prognostic Impact of Metastasis Timing in Metastatic Gastrointestinal Stromal Tumors: A Multicenter Retrospective Cohort Study. Annals of Gastroenterological Surgery, 10(5), 1663-1672. https://doi.org/10.1002/ags3.70245

Image Credits: AI Generated

DOI: 10.1002/ags3.70245

Keywords: gastrointestinal stromal tumors, GIST, metastasis timing, synchronous metastasis, metachronous recurrence, imatinib, tyrosine kinase inhibitors, overall survival, Kinki GIST Registry, early recurrence, KIT mutations, prognosis